Radioimmunotherapy of prostate cancer using90Y- and 177Lu-lebeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Vallabhajosula, Shankar ^a,b   Goldsmith, Stanley J ^a   Kostakoglu, Lale ^a   Milowsky, Mathew I ^a   Nanus, David M ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUTETIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; UNCLASSIFIED DRUG; YTTRIUM 90;

BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CONFERENCE PAPER; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; BONE MARROW; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; LUTETIUM; MALE; MAXIMUM TOLERATED DOSE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; THROMBOCYTOPENIA; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 26444519932     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0023     Document Type: Conference Paper

References (23)

1. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
2. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
3. Wright GL, Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
4. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-35.
5. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
6. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res 2000;60:5237-43.
7. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internaltzation of prostate-specific membrane antigen. Cancer Res 1998;58:4055-60.
8. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urology 2003;170:1717-21.
9. 90Y-labeled anti-PSMA monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
10. 177Lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
11. 177Lu? J Nucl Med 2005;46:634-41.
12. 177Lu labeled J591 antibodies specific to prostate specific membrane antigen (PSMA). J Nucl Med 2005;46:850-8.
13. Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology 1997;11:349-56.
14. Mirzaie-Joniani H, Eriksson D, Sheikholvaezin A, et al. Apoptosis induced by low-dose and low-dose-rate. Radiation Cancer 2002;94:1210-4.
15. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmuno-therapy. Cancer 2002;94:1332-48.
16. Shen S, Duan J, Meredith RF, et al. Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer 2002;94:1264-9.
17. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000;41:538-47.
18. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-1.
19. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 1993;20:571-8.
20. Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S. Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res 1995;55:5881-7.
21. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871-84.
22. 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004;45:1412-21.
23. 90Yttrium-DOTA-peptide-ChL6. Prostate 2002;50:27-37.